Global Cholangitis Therapeutics Market: Overview
Cholangitis is an infection of the biliary tract that leads to significant mortality and morbidity. It is a bacterial infection that occurs when the bile duct that carries bile from the liver to the intestine and gallbladder is blocked by a tumor or gallstone. Bile is a liquid generated by the liver for the digestion of food. Abdominal pain, jaundice, fever, and low blood pressure are some of the symptoms of cholangitis. The presence of pancreatic cancer slightly increases the risk of cholangitis. Several factors lead to the development of cholangitis. They include strictures or blockage of bile duct system, presence of gall stones, swelling of the pancreas, and blood stream infections. Diagnosis and treatment of the infection at an early stage are very important. People above the age of 60 are more prone to this infection.
Global Cholangitis Therapeutics Market: Key Trends
The cholangitis therapeutics market is expected to expand at a rapid pace. Increase in the geriatric population, changes in lifestyle, and increase in health care awareness are some of the important factors driving the growth of the market. Improvement in health care policies leads to an increase in the affordability of various health care treatments. This, in turn, has increased the life expectancy of the population. The population above the age of 65 years usually suffer from various health disorders. Thus, an increase in the geriatric population globally augments the cholangitis therapeutics market. Moreover, a large number of drug candidates are at different stages of clinical trial approval in the U.S. and Europe. The anticipated launch and commercialization of these products is likely to fuel the cholangitis therapeutics market during the forecast period. However, the delayed diagnosis of cholangitis is a key restarting factor for the cholangitis therapeutics market.
Global Cholangitis Therapeutics Market: Segmentation
The global cholangitis therapeutics market can be segmented based on type of cholangitis, drug class, distribution channel, and region. In terms of type of cholangitis, the market can be classified into primary slerosing (PSC), secondary (acute) cholangitis, and IgG4-associated cholangitis (IAC). The primary slerosing segment is estimated to dominate the global cholangitis therapeutics market in the next few years, owing to a significant rise in the incidence rate of primary slerosing cholangitis over the last few years. In terms of drug class, the global market can be categorized into carbapenam, aminoglycosides, cephalosporines, beta lactamase inhibitors, and others. Based on distribution channel, the global cholangitis therapeutics market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Global Cholangitis Therapeutics Market: Regional Analysis
In terms of region, the global cholangitis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are anticipated to account for major shares of the global market, due to a large population afflicted with pancreatitis and related bile duct disorders. Moreover, availability of technologically advanced diagnostic tools and systems, high levels of awareness about cholangitis, and well- established health care infrastructure are likely to fuel the market in North America and Europe during the forecast period. The cholangitis therapeutics market in Asia Pacific is expected to expand at a high CAGR during the forecast period, due to a rise in the prevalence of cholangitis in highly populous countries such as India and China, rapidly changing health care systems, government initiatives to improve overall health care, and increased per capita health care expenditure. Moreover, a rise in investments by leading global diagnostics companies and a large base of pharmaceutical companies in the region are likely to contribute to the growth of the market in Asia Pacific in the near future.
Global Cholangitis Therapeutics Market: Competitive Landscape
Key players operating in the global cholangitis therapeutics market include Dr. Reddy’s laboratories Inc. Pfizer Inc., Novartis AG, Gilead Sciences, Inc., Amneal Pharmaceuticals, Inc., Fresenius Kabi AG, Bayer AG, Par Pharmaceutical Inc., and Merck & Co., Inc..
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.